Sinapsos Podcast | Oncology

E44 - Exercise Program for Cancer Fatigue

E44   |  18 min   |   Latest   |  Publication Link

• Podcast based on: Cano-Uceda, A.; Pareja-García, P.; Sánchez-Rodríguez, E.; Fraguas-Ramos, D.; Martín-Álvarez, L.; Asencio-Vicente, R.; Rivero-de la Villa, A.; Pérez-Pérez, M.d.M.; Obispo-Portero, B.M.; Morales-Ruiz, L.; de Dios-Álvarez, R.; Sanchez-Barroso, L.; De Sousa-De Sousa, L.; Maté-Muñoz, J.L.; García-Fernández, P. Effects of a 6-Week Supervised Multimodal Exercise Program on Cancer-Related Fatigue, Quality of Life and Physical Function During Active Treatment: A Randomized Controlled Trial. Cancers 2026, 18, 947. https://doi.org/10.3390/cancers18060947
  Type: Article  |  Publication date: 13 March 2026
  
  
• Summary: Reduced quality of life, cancer-related fatigue, and functional impairment are common problems during and after cancer treatment. To examine this issue, a randomized clinical trial was conducted with 110 patients with stage I–III cancer. Participants were randomly assigned either to an intervention group, which completed a six-week supervised exercise program, or to a control group that received usual care. The exercise program included cardiorespiratory training, strength exercises, and stretching, with intensity monitored through perceived exertion. Quality of life, fatigue, functional capacity, and muscle strength were assessed. The group that completed the exercise program showed significant and clinically meaningful improvements in fatigue, global quality of life, functional capacity, and muscle strength compared with the control group. Furthermore, a higher percentage of participants in the intervention group achieved improvements considered clinically important. Among symptoms, only insomnia showed a significant reduction. Conclusion: A brief, supervised therapeutic exercise program of moderate to vigorous intensity is safe and effective for improving fatigue, quality of life, and physical function in patients with cancer, and may be suitable for integration into routine oncologic care.
  
  
• Keywords: therapeutic exercise; cancer; quality of life; physical function; fatigue; short-duration intervention

 

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.

 

E43 - Endometrial Cancer Prognosis Study

E43   |  15 min   |   Latest   |  Publication Link

• Podcast based on: Paratore, S.; Russo, A.; Lanzafame, K.; Blanco, G.; Giurato, E.; Bartoloni, G.; D’Asta, M.; Sapienza, M.; Bonanno, G.M.; Vallone, A.; Ettore, G.; Bordonaro, R. Prognostic Stratification of Multiple-Classifier Endometrial Cancers: Cohort Study and Meta-Analysis. Cancers 2026, 18, 929. https://doi.org/10.3390/cancers18060929
  Type: Article  |  Publication date: 12 March 2026
  
  
• Summary: The classification of endometrial cancer has evolved using molecular features, allowing for improved risk assessment and more personalized treatment strategies. However, a small proportion of tumors show more than one relevant molecular alteration, making their classification and clinical management more challenging. This study aimed to characterize molecular and clinicopathological profiles of multiple-classifier endometrial cancers, enhancing our understanding of their biological heterogeneity. In our patient cohort, POLEmut tumors with concurrent MMRd/MSI generally retained the POLE-associated ultramutated profile, while tumors with both MMRd/MSI and p53abn/TP53mut alterations were more often associated with more adverse clinicopathological characteristics compared to MMRd/MSI-only tumors. By integrating our data in a systematic literature review with meta-analysis, we observed that variability in reported incidence is largely driven by differences in testing strategies. These results highlight the limitations of current classification systems and emphasize the importance of more standardized molecular approaches to improve risk stratification and management in endometrial cancer.
  
  
• Keywords: endometrial cancer; molecular profile; clinicopathological features; multiple-classifier; POLE mutated; mismatch repair-deficient; TP53mutated; next generation sequencing

 

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.

 

E42 - Brain Tumor Review Molecular Diversity

E42   |  20 min   |   Latest   |  Publication Link

• Podcast based on: Lee, C.; Park, K.; Park, S.; Kim, M.; Hwang, J. Diffuse Leptomeningeal Glioneuronal Tumor: A Systematic Review Highlighting Molecular Heterogeneity and Survival Outcome. Cancers 2026, 18, 912. https://doi.org/10.3390/cancers18060912
  Type: Systematic Review  |  Publication date: 11 March 2026
  
  
• Summary: Diffuse leptomeningeal glioneuronal tumor is a very rare brain tumor that mainly affects children and young adults and often spreads along the brain and spinal cord. Because it is uncommon and difficult to diagnose, treatment strategies vary widely and clinical outcomes remain unpredictable. To address this, we reviewed all published cases reported since this tumor was first defined to summarize clinical features, genetic findings, treatments, and survival outcomes. We found that hydrocephalus and spinal involvement were common, and that surgery was associated with longer survival in selected patients. Genetic alterations affecting tumor growth–related pathways were also frequently observed. This summary of current evidence may help clinicians recognize this tumor earlier and consider appropriate management strategies.
  
  
• Keywords: diffuse leptomeningeal glioneuronal tumor; leptomeningeal dissemination; BRAF fusion; MAPK pathway; pediatric low-grade glioma; molecular heterogeneity; survival analysis

 

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.

 

E41 - Lipid Changes in Leukemia Diagnosis

E41   |  22 min   |   Latest   |  Publication Link

• Podcast based on: Wojnicka, J.; Kiełbus, M.; Mertowska, P.; Mertowski, S.; Grywalska, E.; Sosnowski, P.; Wielgosz, A.; Kozub-Pędrak, A.; Sosnowska-Pasiarska, B.; Klatka, M.; Klatka, J.; Błażewicz, A. Specific Lipidomic Shifts in Chronic Lymphocytic Leukemia at Diagnosis. Cancers 2026, 18, 896. https://doi.org/10.3390/cancers18060896
  Type: Article  |  Publication date: 10 March 2026
  
  
• Summary: Chronic lymphocytic leukemia (CLL) is a common type of adult blood cancer in which cells survive longer than normal, partly due to changes in how they process fats and other molecules for energy. This study examined the blood plasma of newly diagnosed patients who had not yet received treatment to identify unique patterns in lipid molecules. We found that patients with CLL had higher levels of certain fats, including carnitines and specific phospholipids, compared with healthy individuals. By analyzing these lipid changes using predictive bioinformatics tools, we identified that several pathways involved in lipid metabolism are likely disrupted. These findings improve our understanding of how this disease alters the body’s metabolism and could inform future research on biomarkers for earlier disease detection and treatment development.
  
  
• Keywords: chronic lymphocytic leukemia (CLL); metabolic reprogramming; carnitines; ether-linked phospholipids; lipidomics

 

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.

 

E40 - Frailty Assessments in Lung Cancer Clinics

E40   |  18 min   |   Latest   |  Publication Link

• Podcast based on: Pearce, J.; Hamzeh, H.; Denholm, M.; Greystoke, A.; Gomes, F.; Clegg, A.; Velikova, G.; Richards, S.H.; Gilbert, A. Clinicians’ Experiences of Implementing Clinical Frailty Scale Assessments in Lung Oncology Clinics: A Qualitative Interview Study. Cancers 2026, 18, 884. https://doi.org/10.3390/cancers18050884
  Type: Article  |  Publication date: 09 March 2026
  
  
• Summary: Simple frailty assessments, such as the clinical frailty scale (CFS), could support treatment decision-making and care in cancer clinics, but they are not currently used routinely. This qualitative interview study explored clinicians’ experiences of using frailty assessments in lung cancer clinics to understand how they impact care, and the barriers and facilitators to their use. Four main themes were identified. ‘Assessing fitness and frailty’ explores the central role of performance status in assessing fitness and accessing cancer treatments, as well as its limitations and what frailty assessments add. ‘Scoring and interpreting CFS’ describes the ease and relative yield of CFS use, and its ability to differentiate between patients considered ‘borderline’ according to performance status, as well as the need to consider scoring in the wider clinical context. ‘Role of frailty and impacts of assessment’ highlights how frailty assessments can enhance patient-centred care and support, communication with patients, and clinical and shared decision-making, with the potential to streamline care and convey wider system-level benefits. ‘Barriers and facilitators to implementation’ describes factors that help or hinder the delivery of frailty assessments and frailty-informed care, with specific recommendations provided to support use in practice.
  
  
• Keywords: frailty; geriatric oncology; qualitative research; frailty assessment; frailty screening; clinical frailty scale (CFS); frailty-informed care

 

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.

 

E39 - Nutrition in Pediatric Cancer Care

E39   |  19 min   |   Latest   |  Publication Link

• Podcast based on: Suwannaying, K.; Rujkijyanont, P.; Inaba, H. Nutritional Assessment of Children and Adolescents with Cancer in Various Resource Settings. Cancers 2026, 18, 873. https://doi.org/10.3390/cancers18050873
  Type: Review  |  Publication date: 08 March 2026
  
  
• Summary: Nutrition has bidirectional effects in children with cancer. It influences, and is influenced by, the disease and treatment, starting from the diagnosis and continuing through therapy into survivorship. Therefore, a longitudinal comprehensive nutritional assessment is essential to define the patient’s nutritional status and to guide management. Assessment strategies should be tailored not only to specific cancer types but also to the available health care resources. In this review, we discuss practical methods for evaluating malnutrition, including their advantages and limitations. We also provide a structured approach for use in various resource settings. This approach will guide nutritional management that can enhance treatment outcomes for children with cancer.
  
  
• Keywords: nutrition; assessment; children; cancer; resource-setting

 

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.

 

E38 - mRNA-miRNA Profiling in Ovarian Cancer

E38   |  14 min   |   Latest   |  Publication Link

• Podcast based on: Hablase, R.; Sisu, C.; Karteris, E.; Chatterjee, J. Integrative In Silico mRNA–miRNA Profiling of mTOR Pathway Dysregulation in High-Grade Serous Ovarian Carcinoma. Cancers 2026, 18, 866. https://doi.org/10.3390/cancers18050866
  Type: Article  |  Publication date: 07 March 2026
  
  
• Summary: High-grade serous ovarian cancer (HGSOC) is the most common and aggressive type of ovarian cancer. It is often diagnosed at a late stage and eventually becomes resistant to standard chemotherapy. The mechanistic target of rapamycin (mTOR) is a key regulator of cellular functions including growth, survival, immune responses, and metabolism. To show how the mTOR pathway becomes dysregulated in HGSOC, we analysed gene expression data and microRNA patterns from both ovarian cancer patients and healthy individuals. We found that many of the genes involved in the mTOR pathway are unusually dysregulated. A group of regulatory molecules, the let-7 miRNAs, may allow this abnormal activity to continue. We also discovered a distinct pattern where one part of the pathway (mTORC1) is switched on while another (mTORC2) is switched off. These findings may help guide more effective, targeted treatments in the future targeting these pathways.
  
  
• Keywords: ovarian cancer; mTOR; TCGA; GTEx; miRNA

 

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.

 

E37 - Addressing Disparities in Thoracic Oncology Care

E37   |  16 min   |   Latest   |  Publication Link

• Podcast based on: Awlad Mohammad, M.W.; Abu Hashhash, K.; Yacoub, R.; Abu Akar, F. Disparities in Thoracic Oncology Patients. Cancers 2026, 18, 793. https://doi.org/10.3390/cancers18050793
  Type: Review  |  Publication date: 28 February 2026
  
  
• Summary: Lung cancer continues to be a predominant cause of cancer-related mortality globally; however, not all individuals experience equal advantages from advancements in screening, diagnosis, and treatment. Countless individuals from underprivileged backgrounds face elevated risks, delayed diagnoses, and worse access to adequate healthcare, resulting in adverse consequences. This review aimed to elucidate the impact of social, economic, racial, and geographic determinants on lung cancer along the continuum of care, encompassing risk exposure, early detection, treatment, and survival outcomes. The authors intend to consolidate existing research to elucidate the locations and reasons for these inequalities and their impact on patient outcomes. The results underscore that enhancing lung cancer survival necessitates not only medical advancements but also equitable access to screening, prompt diagnosis, effective treatment, and involvement in research. This study may inform future research, policy, and healthcare practices aimed at achieving equitable lung cancer care for all demographics.
  
  
• Keywords: lung cancer; disparities; epidemiology treatment; screening

 

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.

 

E36 - ER-Negative Endometrial Cancer Diagnosis and Implications

E36   |  20 min   |   Latest   |  Publication Link

• Podcast based on: Fan, R.; Wei, X.; Lea, J.; Zhu, H.; Zheng, W. ER-Negative Endometrial Cancers: An Evolving Diagnostic Category with Major Clinical Implications. Cancers 2026, 18, 773. https://doi.org/10.3390/cancers18050773
  Type: Review  |  Publication date: 27 February 2026
  
  
• Summary: Estrogen receptor–negative (ER-negative) endometrial carcinomas represent a biologically aggressive and heterogeneous subset of endometrial cancers. Although ER testing has long been used in endometrial carcinoma, it has historically been applied mainly for therapeutic decision-making rather than as a diagnostic tool. Loss of ER expression is associated with poor prognosis but, by itself, is insufficient for accurate tumor classification. In this commentary, we review the evolving diagnostic significance of ER negativity using an integrated framework that incorporates tumor morphology, immunophenotypic features, and molecular heterogeneity. We highlight several high-grade ER-negative tumor types—including gastrointestinal-type adenocarcinoma, pilomatrix-like carcinoma, mesonephric-like adenocarcinoma, clear cell carcinoma, and other high-grade ER-negative carcinomas—that show distinct clinicopathologic characteristics. We propose that ER negativity should be regarded as a diagnostic signal that prompts careful subclassification, with important implications for accurate diagnosis and clinical management.
  
  
• Keywords: estrogen receptor–negative (ER-negative) endometrial carcinomas; endometrial gastrointestinal-type adenocarcinoma; pilomatrix-like high-grade endometrial carcinoma; PiMHEC; mesonephric-like adenocarcinoma

 

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.

 

E35 - AI-Driven Drug Repurposing for Head and Neck Cancer

E35   |  18 min   |   Latest   |  Publication Link

• Podcast based on: Tanikella, P.; Nenad, W.; Courtine, C.; Dai, Y.; Deng, Q.; Zou, B.; Osazuwa-Peters, N.; Schrank, T.P.; Wu, D. GARD: Genomic Data-Based Drug Repurposing in Head and Neck Cancer with Large Language Model Validation. Cancers 2026, 18, 757. https://doi.org/10.3390/cancers18050757
  Type: Article  |  Publication date: 26 February 2026
  
  
• Summary: Head and neck cancer (HNC) is among the most prevalent and challenging cancers worldwide. Developing new drugs is expensive and time consuming, so this study explored a faster, cost-effective approach utilizing existing medications with established safety profiles: drug repurposing. We developed the GARDpipeline (Genomic Alteration-based Repurposing for Drugs), which utilizes large-scale genomic data from The Cancer Genome Atlas (TCGA) to identify key genomic changes in HNC. These genes are expanded through protein–protein interaction networks to capture related pathways and then validated using evidence from thousands of PubMed articles extracted by large language model (LLM) tools. Finally, validated genes are matched with drugs using the DrugBank database. This approach uncovered both known cancer drugs and promising new candidates. These included targeted therapies such as Fostamatinib, Nintedanib, Brigatinib, Regorafenib, and Lenvatinib, as well as emerging compounds like Artenimol, Quercetin, and Acetylsalicylic Acid (Aspirin). Through a combination of genomic analysis, network expansion, and literature validation, the GARD pipeline offers a powerful way to accelerate personalized cancer treatments while reducing cost and development time.
  
  
• Keywords: head and neck cancer; drug repurposing; genomics

 

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.

 

E34 - Managing Toxicities in GEP-NETs After Radioligand Therapy

E34   |  21 min   |   Latest   |  Publication Link

• Podcast based on: El-Haddad, G.; Gardner, L.; Kim, H.; Soares, H.P. Occurrence and Management of Acute, Subacute, and Delayed Toxicities in Patients with GEP-NETs Following Treatment with Radioligand Therapy. Cancers 2026, 18, 742. https://doi.org/10.3390/cancers18050742
  Type: Review  |  Publication date: 25 February 2026
  
  
• Summary: Radioligand therapy is a type of treatment being developed for many cancer types, including gastroenteropancreatic neuroendocrine tumors (GEP-NETs). It uses specially designed drugs to deliver radiation directly to tumor cells within the body. Studies have shown that radioligand therapies can help some patients with GEP-NETs to live longer without disease progression. However, side effects have been reported in patients treated with radioligand therapies. Additionally, there is a risk of radiation exposure among people who come into contact with treated patients. In this article, we provide practical strategies to prevent and manage the side effects of radioligand therapy and to maintain radiation safety.
  
  
• Keywords: radioligand therapy; gastroenteropancreatic neuroendocrine tumors; adverse event; toxicity; management; radioactive contamination; radiation safety

 

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.

 

E33 - Biopsy Tumor Burden vs AI in Prostate Cancer Grading

E33   |  14 min   |   Latest   |  Publication Link

• Podcast based on: Condoiu, C.; Baloi, A.; Sandesc, D.; Cumpanas, A.A.; Latcu, S.; Dema, V.; Caprariu, R.; Barb, A.C.; Ciucurita, A.; Marinescu, A.; Cut, T.G.; Bardan, R. Clinically Significant ISUP Upgrading in the Multiparametric MRI Era: Biopsy Tumor Burden Outperforms Complex Machine Learning Models in a Single-Center Exploratory Cohort. Cancers 2026, 18, 730. https://doi.org/10.3390/cancers18050730
  Type: Article  |  Publication date: 24 February 2026
  
  
• Summary: Sometimes, a prostate biopsy underestimates how aggressive the cancer is. This study looked at ways to predict when the final surgery will find a higher-grade cancer than the initial biopsy. We analyzed 96 men who had both a biopsy and their prostate removed. We focused on factors like PSA (a blood test for prostate cancer), MRI scans, and biopsy results. We found that the extent of cancer involvement in biopsy cores, and to a lesser degree PSA density, were associated with upgrading risk to a more aggressive cancer at surgery. Using just these two factors, a simple statistical model predicted grade upgrading more accurately than more complex computer models. If confirmed in larger studies, this tool could help doctors identify patients who have more aggressive cancer than initially thought, so they can choose the best treatment.
  
  
• Keywords: prostate cancer; precision medicine; artificial intelligence; personalized treatment; imaging modalities; risk stratification; ISUP upgrading; PSA density; positive core ratio; multiparametric MRI

 

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.

 

E32 - Biomarkers for Immunotherapy Response in Kidney Cancer

E32   |  18 min   |   Latest   |  Publication Link

• Podcast based on: Katifelis, H.; Zerva, S.; Bamias, A.; Karamouzis, M.V.; Stravodimos, K.; Sechi, L.A.; Lampropoulou, D.; Pliakou, E.; Gazouli, M. Circulating ERVFRD-1 and MFSD2A Are Associated with Immunotherapy Response in Metastatic Clear Cell Renal Cell Carcinoma. Cancers 2026, 18, 716. https://doi.org/10.3390/cancers18040716
  Type: Article  |  Publication date: 23 February 2026
  
  
• Summary: Immune checkpoint inhibitor (ICI) therapies have improved outcomes for patients with metastatic clear cell renal cell carcinoma (mccRCC). However, many patients do not respond to treatment. Therefore, reliable biomarkers associated with therapeutic response are urgently needed. Blood-based biomarkers offer a non-invasive alternative to tissue analysis. In this study, we investigated the expression of two immunity-related genes, ERVFRD-1 and MFSD2A, in peripheral blood samples from mccRCC patients receiving PD-1-based treatment. Both genes were dysregulated compared with healthy controls and demonstrated differential baseline expression between patients who achieved clinical benefit and those with progressive disease. Patients with progressive disease exhibited decreased expression of ERVFRD-1 and increased expression of MFSD2A. These findings suggest that ERVFRD-1 and MFSD2A may serve as candidate blood-based biomarkers associated with response to ICI, although confirmation in larger prospective studies is required.
  
  
• Keywords: ccRCC; immunotherapy; ICIs; PD-1; TKI; ;

 

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.

 

E31 - TIC TOC Trial Cell Salvage vs Transfusion in Ovarian Cancer

E31   |  17 min   |   Latest   |  Publication Link

• Podcast based on: Galaal, K.; Vickery, P.J.; Marques, E.; Palmer, J.; Jones, B.; O’Shaughnessy, E.; Lopes, A.; Ewings, P.; Bekkers, R.L.M. The Trial of Intraoperative Cell Salvage Versus Transfusion in Ovarian Cancer (TIC TOC): Results of a Randomized Controlled Feasibility Study. Cancers 2026, 18, 711. https://doi.org/10.3390/cancers18040711
  Type: Article  |  Publication date: 22 February 2026
  
  
• Summary: This study looked at whether it is acceptable to use intraoperative cell salvage (ICS) during surgery for women with advanced (stage 3–4) ovarian cancer. ICS is a method that collects a patient’s own blood lost during surgery, cleans it, and gives it back to them, reducing the need for donated blood. A total of 57 women with ovarian cancer took part; the amount of blood loss during surgery was similar in both groups. In the ICS group, about two-thirds of the women who had surgery received their own salvaged blood. Women appeared comfortable with the idea of receiving their own salvaged blood. Overall, this study shows that using ICS in ovarian cancer surgery is both feasible and acceptable to patients. The findings suggest that a larger trial should now be carried out to determine whether ICS can reduce the need for donor blood and improve patient outcomes.
  
  
• Keywords: intraoperative cell salvage; blood transfusion; cytoreductive surgery; ovarian cancer; randomized feasibility trial

 

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.

 

E30 - Automating Cancer Pain Assessment

E30   |  11 min   |   Latest   |  Publication Link

• Podcast based on: Cascella, M.; Perri, F.; Ottaiano, A.; Santorsola, M.; Marciano, M.L.; Rampetta, F.R.; Pontone, M.; Crispo, A.; Sabbatino, F.; Franci, G.; Esposito, W.; Cisale, G.; Romano, M.; Amato, F.; Scuotto, A.; Santoriello, V.; Ponsiglione, A.M. Linking Cancer Pain Features and Biosignals for Automatic Pain Assessment. Cancers 2026, 18, 646. https://doi.org/10.3390/cancers18040646
  Type: Article  |  Publication date: 16 February 2026
  
  
• Summary: Although pain is a frequent and burdensome symptom in people with cancer, it is commonly evaluated using self-reported scales that may be unreliable in patients with cognitive, communicative, or clinical limitations. This study explored whether objective physiological signals could enhance cancer pain assessment. We analyzed electrodermal activity and heart rate variability recorded in cancer patients and examined their relationships with pain intensity and pain type. The results indicate that specific electrodermal activity parameters are associated with both pain intensity and distinct pain phenotypes (mainly mixed pain). In contrast, heart rate variability failed to provide meaningful discrimination in this context. Despite limitations, these findings suggest that electrodermal activity may represent a valuable objective marker to complement conventional pain scales and support the development of automated pain assessment approaches in oncology.
  
  
• Keywords: cancer pain; breakthrough cancer pain; biosignals; electrodermal activity; automatic pain assessment; heart rate variability

 

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.

 

E29 - Menin Inhibition New Target for Leukemia

E29   |  12 min   |   Latest   |  Publication Link

• Podcast based on: Alati, C.; Molica, M.; Pitea, M.; Marafioti, V.; Porto, G.; Policastro, G.; Bilardi, E.; Utano, G.; Giordano, L.; Sgarlata, A.; Delfino, I.M.; Idato, A.; Santoro, G.; Rossi, M.; Martino, M. Menin Inhibition in Acute Myeloid MLL Rearranged Leukemias: A New Target for Precision Care. Cancers 2026, 18, 637. https://doi.org/10.3390/cancers18040637
  Type: Review  |  Publication date: 15 February 2026
  
  
• Summary: Menin inhibitors are new targeted drugs for two high-risk types of acute leukemia (KMT2A-rearranged and NPM1-mutated). Revumenib was approved in 2024–2025. In heavily pretreated patients, about 23% achieved complete remission, with most of those becoming MRD-negative. Ziftomenib, bleximenib, and enzomenib show similar effectiveness but differ in side effects, particularly heart rhythm problems (QTc prolongation varies among drugs). When combined with other drugs like azacitidine/venetoclax or chemotherapy, response rates are much higher in newly diagnosed patients, suggesting these could work as initial treatment. About 40% of patients develop resistance, usually through MEN1 gene mutations. Different menin inhibitors have different resistance patterns, so switching drugs might help. About 30–40% of responders went on to stem cell transplant, which remains the best chance for cure. Menin inhibitors are the first targeted therapies for these aggressive leukemias, showing promise both alone and in combinations, though resistance remains a challenge.
  
  
• Keywords: menin inhibitors; KMT2A rearrangements; MLL rearrangements; NPM1 mutations; acute myeloid leukemia; revumenib; precision medicine; targeted therapy

 

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.

 

E28 - Reducing Pancreatic Surgery Complications

E28   |  13 min   |   Latest   |  Publication Link

• Podcast based on: Karpes, J.B.; Liu, K.; Crawford, M.D.; Pulitano, C.; Sandroussi, C.; Laurence, J.M. Reducing Complications in Pancreaticoduodenectomy. Cancers 2026, 18, 630. https://doi.org/10.3390/cancers18040630
  Type: Review  |  Publication date: 14 February 2026
  
  
• Summary: Pancreatic surgery is one of the most complex areas of abdominal surgery, with morbidity and mortality remaining a major challenge. Despite progress in surgical techniques and perioperative care, outcomes still vary widely, and there is no consensus on how to reliably prevent major complications. This study evaluates contemporary evidence on how complications develop, how they can be detected early, and the strategies that may reduce their frequency and impact. The evaluation includes technical factors during surgery, as well as non-technical factors outside of the operating theatre that may improve safety and outcomes. The goal of this review is to guide practice and future research to improve the safety of pancreatic resection in any environment.
  
  
• Keywords: pancreaticoduodenectomy; postoperative pancreatic fistula; centralisation; failure to rescue

 

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.

 

E27 - Histotripsy Boosts Survival in Brain Cancer

E27   |  12 min   |   Latest   |  Publication Link

• Podcast based on: Duclos, S.; Kaovasia, T.P.; Fox, A.; Cornett, A.; Pandey, A.S.; Xu, Z. First Report of Histotripsy-Induced Survival Benefit in Murine Glioblastomas. Cancers 2026, 18, 622. https://doi.org/10.3390/cancers18040622
  Type: Article  |  Publication date: 13 February 2026
  
  
• Summary: Histotripsy is a noninvasive soft tissue ablation technique that uses high-pressure ultrasound to generate precise regions of cellular destruction within tumors while sparing surrounding healthy tissue. This study evaluated the survival benefit of a single transcranial histotripsy treatment in glioblastoma-bearing mice using a raster-scanning pattern with varying numbers of histotripsy pulses. Histotripsy resulted in an 18.5% increase in survival compared with untreated controls and was well tolerated with no significant acute or chronic adverse effects. These findings support further investigation of histotripsy as a potential therapeutic approach for brain tumors.
  
  
• Keywords: glioblastoma; murine model; transcranial histotripsy

 

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.

 

E26 - Advances in Liver Cancer Treatment

E26   |  13 min   |   Latest   |  Publication Link

• Podcast based on: Morishita, A.; Oura, K.; Tai, H.; Yano, R.; Nakahara, M.; Tadokoro, T.; Fujita, K.; Mimura, S.; Tani, J.; Tatsuta, M.; Himoto, T.; Kobara, H. Advances in the Therapeutic Landscape of Hepatocellular Carcinoma: Current Strategies and Future Perspectives. Cancers 2026, 18, 609. https://doi.org/10.3390/cancers18040609
  Type: Review  |  Publication date: 12 February 2026
  
  
• Summary: Hepatocellular carcinoma (HCC) arises mostly in chronically diseased livers, so clinicians must manage both an aggressive cancer and a fragile organ simultaneously. This review explains how modern HCC care has evolved into an integrated continuum: from prevention and surveillance to curative options such as resection, ablation, and transplantation, to refined locoregional therapy and immunotherapy-based systemic regimens. We highlight how treatment decisions are tailored according to tumor stage, liver function, portal hypertension, and frailty, and why preserving hepatic reserve is crucial to allow multiple lines of therapy. We also summarize emerging tools such as biomarkers, liquid biopsy, radiomics, and microbiome research that may support more precise treatment selection. Finally, we discuss special populations, safety considerations, and future strategies that combine innovative and traditional approaches to improve survival and quality of life for patients with HCC worldwide. This review aims to guide practical clinical decision-making.
  
  
• Keywords: hepatocellular carcinoma; cirrhosis; surveillance; Barcelona Clinic Liver Cancer; transarterial chemoembolization; radioembolization; stereotactic body radiotherapy; immune checkpoint inhibitor; tyrosine kinase inhibitor; biomarkers

 

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.

 

E25 - Eribulin s Effect on Breast Cancer Plasticity

E25   |  12 min   |   Latest   |  Publication Link

• Podcast based on: Bidgood, C.L.; Morera, E.; Jaradi, B.; van Wyngaard, T.; Koikalethu, A.T.; Bock, N.; Agarwal, V.; Redfern, A.D.; Thompson, E.W. Effects of Eribulin on Epithelial–Mesenchymal Plasticity in Patient-Derived Breast Cancer Cultures and Excised Tissues. Cancers 2026, 18, 598. https://doi.org/10.3390/cancers18040598
  Type: Article  |  Publication date: 11 February 2026
  
  
• Summary: Eribulin is an approved therapy for the treatment of breast cancer which has been shown to reverse the epithelial-to-mesenchymal transition (EMT) and improve the efficacy of standard chemotherapies in cell lines, animal studies, and clinical specimens. Tumour EMT status has also been linked to eribulin efficacy. Based on this, we evaluated the effects of eribulin in patient-derived breast cancer cultures and a triple-negative breast cancer cell line to assess changes to EMT and therapy response. We further identified the induction of epithelial-like characteristics, including E-cadherin expression in a patient-derived HER2+ primary tissue with a predominantly mesenchymal phenotype following longitudinal eribulin exposure. Additionally, we compared EMT marker expression in breast cancers treated with standard-of-care neoadjuvant docetaxel, Adriamycin and cyclophosphamide (TAC) therapy with that observed in the neoadjuvant eribulin clinical trial.
  
  
• Keywords: breast cancer; eribulin; EMT; chemoresistance

 

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.